Richard Lewis at Amgen to Speak at the 7th Protein Kinases Conference – May 30-31, 2012 in Boston
Richard Lewis, Principal Scientist, Amgen to give a Presentation on “The Discovery & Optimisation of a Novel Class of Potent, Selective and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer” at the 7th Protein Kinases in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)
View full press release